微小RNA与肝癌肝移植术后肿瘤复发的研究进展

赵之聪; 王健东

doi:10.3969/j.issn.1674-7445.2017.03.014

微小RNA与肝癌肝移植术后肿瘤复发的研究进展

doi: 10.3969/j.issn.1674-7445.2017.03.014

赵之聪,
王健东^,

200092 上海交通大学医学院附属新华医院普外科

基金项目:

国家十二五科技重大专项 2012ZX10002016014

详细信息

通讯作者:
王健东，Email：wangjiandongdr@163.com

中图分类号: R617, R735.7
计量
- 文章访问数: 100
- HTML全文浏览量: 18
- PDF下载量: 5
- 被引次数: 0
出版历程
- 收稿日期: 2017-01-30
- 网络出版日期: 2021-01-19
- 刊出日期: 2017-05-15

摘要

摘要: 肝细胞癌（肝癌）是全球最常见的恶性肿瘤之一，肝移植是失去根治性切除机会或伴有失代偿性肝硬化肝癌患者唯一有效的治疗方法。然而肝癌肝移植术后肿瘤复发依然严重影响了患者的预后，这也是近年来肝移植领域的研究热点。微小核糖核酸（miRNA）是一类真核细胞中广泛存在长度约21~23 nt的非编码RNA，目前的研究认为miRNA与肝癌肝移植术后肿瘤复发密切相关。联合应用检测miRNA与米兰标准有可能进一步提高肝移植受者的无瘤生存期。miRNA具有调节肿瘤细胞生物学行为的功能，可能成为肝移植术后肿瘤复发的潜在治疗靶点。本文总结了近年来miRNA与肝癌肝移植术后肿瘤复发的相关研究，为肝移植临床医师及科研工作者提供了新的思路。
- 微小核糖核酸（miRNA）循环微小核糖核酸 /
- 循环微小核糖核酸 /
- 肝细胞癌 /
- 肝移植 /
- 米兰标准 /
- 复发 /
- 预测 /
- 治疗 /
- 甲胎蛋白（AFP） /
- 实时定量聚合酶链反应（qRT-PCR）

HTML全文

参考文献(34)

[1]	Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2):87-108.DOI: 10.3322/caac.21262.
[2]	Yang JD, Roberts LR. Epidemiology and management of hepatocellular carcinoma[J]. Infect Dis Clin North Am, 2010, 24(4):899-919. DOI: 10.1016/j.idc.2010.07.004.
[3]	Mazzola A, Costantino A, Petta S, et al. Recurrence of hepatocellular carcinoma after liver transplantation:an update[J]. Future Oncol, 2015, 11(21):2923-2936. DOI: 10.2217/fon.15.239.
[4]	王征, 周俭.肝癌肝移植术后的综合治疗[J].中华肝脏病杂志, 2013, 21(5):324-325. DOI: 10.3760/cma.j.issn.1007-3418.2013.05.002.Wang Wang Z, Zhou J. Combined modality therapy for recurrent hepatocellular carcinoma following liver transplantation[J]. Chin J Hepatol, 2013, 21(5):324-325. DOI: 10.3760/cma.j.issn.1007-3418.2013.05.002.
[5]	Fahrner R, Dondorf F, Ardelt M, et al. Liver transplantation for hepatocellular carcinoma -factors influencing outcome and disease-free survival[J].World J Gastroenterol, 2015, 21(42):12071-12082. DOI: 10.3748/wjg.v21.i42.12071.
[6]	彭志海, 孙红成.肝癌肝移植术后肝癌复发[J].中华消化外科杂志, 2016, 15(5):444-447. DOI: 10.3760/cma.j.issn.1673-9752.2016.05.009.Peng Peng ZH, Sun HC. Hepatocellular carcinoma recurrence after liver transplantation[J]. Chin J Dig Surg, 2016, 15(5):444-447. DOI: 10.3760/cma.j.issn.1673-9752.2016.05.009.
[7]	Pommergaard HC, Burcharth J, Rosenberg J, et al. Serologic and molecular biomarkers for recurrence of hepatocellular carcinoma after liver transplantation: a systematic review and meta-analysis[J].Transplant Rev (Orlando), 2016, 30(3):171-177. DOI: 10.1016/j.trre.2016.03.001.
[8]	Hung CH, Chiu YC, Chen CH, et al. MicroRNAs in hepatocellular carcinoma: carcinogenesis, progression, and therapeutic target[J]. Biomed Res Int, 2014:486407. DOI: 10.1155/2014/486407.
[9]	Farid WR, Verhoeven CJ, de Jonge J, et al. The ins and outs of microRNAs as biomarkers in liver disease and transplantation[J]. Transpl Int, 2014, 27(12)1222-1232.DOI: 10.1111/tri.12379.
[10]	Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function[J]. Cell, 2004, 116(2):281-297. doi: 10.1016/S0092-8674(04)00045-5
[11]	Ambros V. The functions of animal microRNAs[J].Nature, 2004, 431(7006):350-355. doi: 10.1038/nature02871
[12]	Borel F, Konstantinova P, Jansen PL. Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma[J].J Hepatol, 2012, 56(6):1371-1383. DOI: 10.1016/j.jhep.2011.11.026.
[13]	Zhu Z, Zhang X, Wang G, et al. Role of microRNAs in hepatocellular carcinoma[J]. Hepat Mon, 2014, 14(8):e18672. DOI: 10.5812/hepatmon.18672.
[14]	Tomimaru Y, Eguchi H, Nagano H, et al. Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma[J]. J Hepatol, 2012, 56(1):167-175. DOI: 10.1016/j.jhep.2011.04.026.
[15]	Fu Y, Wei X, Tang C, et al. Circulating microRNA-101 as a potential biomarker for hepatitis B virus-related hepatocellular carcinoma[J]. Oncol Lett, 2013, 6(6):1811-1815. DOI: 10.3892/ol.2013.1638.
[16]	Xie QY, Almudevar A, Whitney-Miller CL, et al. A microRNA biomarker of hepatocellular carcinoma recurrence following liver transplantation accounting for within-patient heterogeneity[J]. BMC Med Genomics, 2016, 9:18. DOI: 10.1186/s12920-016-0179-4.
[17]	Liese J, Peveling-Oberhag J, Doering C, et al. A possible role of microRNAs as predictive markers for the recurrence of hepatocellular carcinoma after liver transplantation[J]. Transpl Int, 2016, 29(3):369-380. DOI: 10.1111/tri.12733.
[18]	Xu X, Ling Q, Wang J, et al. Donor miR-196a-2 polymorphism is associated with hepatocellular carcinoma recurrence after liver transplantation in a Han Chinese population[J]. Int J Cancer, 2016, 138(3):620-629. DOI: 10.1002/ijc.29821.
[19]	Li QG, Yang GS, Yang Q, et al. Disseminated tumor cells homing into rats' liver: a new possible mechanism of HCC recurrence[J]. World J Gastroenterol, 2004, 10(6):903-905. http://pubmedcentralcanada.ca/pmcc/articles/PMC4726996/
[20]	Morita K, Shirabe K, Taketomi A, et al. Relevance of microRNA-18a and microRNA-199a-5p to hepatocellular carcinoma recurrence after living donor liver transplantation[J]. Liver Transpl, 2016, 22(5):665-676. DOI: 10.1002/lt.24400.
[21]	Wu LM, Ji JS, Yang Z, et al. Oncogenic role of microRNA-423-5p in hepatocellular carcinoma[J]. Hepatobiliary Pancreat Dis Int, 2015, 14(6):613-618. doi: 10.1016/S1499-3872(15)60038-8
[22]	Feng J, Wang J, Chen M, et al. miR-200a suppresses cell growth and migration by targeting MACC1 and predicts prognosis in hepatocellular carcinoma[J]. Oncol Rep, 2015, 33(2):713-720. DOI: 10.3892/or.2014.3642.
[23]	Tan YL, Bai ZG, Zou WL, et al. miR-744 is a potential prognostic marker in patients with hepatocellular carcinoma[J]. Clin Res Hepatol Gastroenterol, 2015, 39(3):359-365. DOI: 10.1016/j.clinre.2014.09.010.
[24]	Han ZB, Chen HY, Fan JW, et al. Up-regulation of microRNA-155 promotes cancer cell invasion and predicts poor survival of hepatocellular carcinoma following liver transplantation[J]. J Cancer Res Clin Oncol, 2012, 138(1):153-161. DOI: 10.1007/s00432-011-1076-z.
[25]	Hu G, Drescher KM, Chen XM. Exosomal miRNAs: biological properties and therapeutic potential[J]. Front Genet, 2012, 3:56. DOI: 10.3389/fgene.2012.00056.
[26]	Ng KT, Lo CM, Wong N, et al. Early-phase circulating miRNAs predict tumor recurrence and survival of hepatocellular carcinoma patients after liver transplantation[J]. Oncotarget, 2016, 7(15):19824-19839. DOI: 10.18632/oncotarget.7627.
[27]	Sugimachi K, Matsumura T, Hirata H, et al. Identification of a bona fide microRNA biomarker in serum exosomes that predicts hepatocellular carcinoma recurrence after liver transplantation[J]. Br J Cancer, 2015, 112(3):532-538. DOI: 10.1038/bjc.2014.621.
[28]	Park JK, Kogure T, Nuovo GJ, et al. miR-221 silencing blocks hepatocellular carcinoma and promotes survival[J]. Cancer Res, 2011, 71(24):7608-7616. DOI: 10.1158/0008-5472.CAN-11-1144.
[29]	Kota J, Chivukula RR, O'Donnell KA, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model[J].Cell, 2009, 137(6):1005-1017. DOI: 10.1016/j.cell.2009.04.021.
[30]	Sposito C, Mariani L, Germini A, et al. Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case-control study[J]. J Hepatol, 2013, 59(1):59-66. DOI: 10.1016/j.jhep.2013.02.026.
[31]	Xu Y, Huang J, Ma L, et al. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways[J]. Cancer Lett, 2016, 371(2):171-181. DOI: 10.1016/j.canlet.2015.11.034.
[32]	Yang F, Zhang L, Wang F, et al. Modulation of the unfolded protein response is the core of microRNA-122-involved sensitivity to chemotherapy in hepatocellular carcinoma[J]. Neoplasia, 2011, 13(7):590-600. doi: 10.1593/neo.11422
[33]	Xu J, Lin H, Li G, et al. The miR-367-3p increases sorafenib chemotherapy efficacy to suppress hepatocellular carcinoma metastasis through altering the androgen receptor signals[J]. Ebiomedicine, 2016, 12:55-67. DOI: 10.1016/j.ebiom.2016.07.013.
[34]	Cai D, He K, Chang S, et al. MicroRNA-302b enhances the sensitivity of hepatocellular carcinoma cell lines to 5-FU via targeting Mcl-1 and DPYD[J]. Int J Mol Sci, 2015, 16(10):23668-23682. DOI: 10.3390/ijms161023668.